FindTrial
Sign In

Monclonal B-cell Lymphocytosis; clinical and biological characteristics

Monclonal B-cell Lymphocytosis; clinical and biological characteristics - Monoclonal B-cell Lymphocytosis

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON34393
Enrollment
40
Registered
2010-12-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic leukemia Monoclonal B-cell Lymphocytosis

Interventions

None listed

Sponsors

Sint Antonius Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients over the age of 18 years who were diagnosed with MBL or CLL ever since March 2001 are eligible for the study.

Exclusion criteria

Exclusion criteria: Psychiatric disease or inability to give informed consent

Design outcomes

Primary

MeasureTime frame
- Characterisation of cell surface markers of MBL patients compared to an age-matched control group from general population and to CLL patients. - Gene expression levels of MBL patients compared to normal B-lymphocytes and to CLL patients.—

Secondary

MeasureTime frame
- Descriptive analysis of incidence of infections and antibiotics usage in patients with MBL. - Characterisation of cell surface markers of non-progressive MBL patients versus progressive MBL patients - Characterisation of gene expression levels of non-progressive MBL patients versus progressive MBL patients.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)